The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

BACKGROUND: New oncology drugs are being developed in conjunction with companion diagnostics with approval restricting their use to certain biomarker-positive subgroups. We examined the impact of different predictive biomarker screening techniques and population enrichment criteria on the cost-effec...

Descripción completa

Detalles Bibliográficos
Autores principales: Atherly, A J, Camidge, D R
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2012
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304427/
https://www.ncbi.nlm.nih.gov/pubmed/22374459
http://dx.doi.org/10.1038/bjc.2012.60

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3304427/
https://www.ncbi.nlm.nih.gov/pubmed/22374459
http://dx.doi.org/10.1038/bjc.2012.60

Ejemplares similares